Strides Pharma Science Limited (STAR.BO)
INR 702.0
(1.56%)
INR 702.0
(1.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 25.16 Billion INR | -16.92% |
| 2022 | 30.29 Billion INR | 0.15% |
| 2021 | 30.25 Billion INR | 28.82% |
| 2020 | 23.48 Billion INR | 5.08% |
| 2019 | 22.34 Billion INR | -30.81% |
| 2018 | 32.29 Billion INR | 27.78% |
| 2017 | 25.27 Billion INR | -16.62% |
| 2016 | 30.31 Billion INR | -14.6% |
| 2015 | 35.49 Billion INR | 303.77% |
| 2014 | 8.79 Billion INR | 60.84% |
| 2013 | 5.46 Billion INR | -65.72% |
| 2012 | 15.94 Billion INR | -39.67% |
| 2011 | 26.42 Billion INR | 31.49% |
| 2010 | 20.09 Billion INR | 37.96% |
| 2009 | 14.56 Billion INR | 11.89% |
| 2008 | 13.02 Billion INR | 1.93% |
| 2007 | 12.77 Billion INR | 131.47% |
| 2006 | 5.51 Billion INR | 26.29% |
| 2005 | 4.36 Billion INR | 99.62% |
| 2004 | 2.18 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 22.15 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 25.16 Billion INR | -16.92% |
| 2023 Q4 | 25.16 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 27.94 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 30.29 Billion INR | 0.15% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 31.15 Billion INR | 0.0% |
| 2022 Q4 | 30.29 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 30.25 Billion INR | 28.82% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 27.61 Billion INR | 0.0% |
| 2021 Q4 | 30.25 Billion INR | 0.0% |
| 2020 Q4 | 23.48 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 22.28 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 23.48 Billion INR | 5.08% |
| 2019 Q4 | 22.34 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 20.43 Billion INR | 0.0% |
| 2019 FY | 22.34 Billion INR | -30.81% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 32.29 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 28.71 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 32.29 Billion INR | 27.78% |
| 2017 Q4 | 25.27 Billion INR | 0.0% |
| 2017 FY | 25.27 Billion INR | -16.62% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 32.97 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 30.31 Billion INR | 0.0% |
| 2016 Q2 | 34.78 Billion INR | 0.0% |
| 2016 FY | 30.31 Billion INR | -14.6% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q4 | 35.49 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 21.81 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 35.49 Billion INR | 303.77% |
| 2014 FY | 8.79 Billion INR | 60.84% |
| 2014 Q4 | 8.79 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 5.46 Billion INR | -65.72% |
| 2012 FY | 15.94 Billion INR | -39.67% |
| 2011 FY | 26.42 Billion INR | 31.49% |
| 2010 FY | 20.09 Billion INR | 37.96% |
| 2009 FY | 14.56 Billion INR | 11.89% |
| 2008 FY | 13.02 Billion INR | 1.93% |
| 2007 FY | 12.77 Billion INR | 131.47% |
| 2006 FY | 5.51 Billion INR | 26.29% |
| 2005 FY | 4.36 Billion INR | 99.62% |
| 2004 FY | 2.18 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -7033.971% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -145526.627% |
| Sigachi Industries Limited | 1.43 Billion INR | -1659.409% |
| Bal Pharma Limited | 1.39 Billion INR | -1702.287% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -15042.134% |
| Medico Remedies Limited | 80.5 Million INR | -31163.85% |
| Lasa Supergenerics Limited | 220.76 Million INR | -11300.807% |
| Venus Remedies Limited | 413.3 Million INR | -5989.681% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -4015.887% |
| Alpa Laboratories Limited | 52.46 Million INR | -47872.267% |
| Nectar Lifesciences Limited | 6.35 Billion INR | -296.022% |
| Shilpa Medicare Limited | 9.37 Billion INR | -168.498% |
| Aarti Drugs Limited | 5.64 Billion INR | -346.039% |
| Lupin Limited | 29.21 Billion INR | 13.858% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 62.139% |
| Zydus Lifesciences Limited | 8.04 Billion INR | -212.965% |
| Windlas Biotech Limited | 36.41 Million INR | -69025.652% |
| Suven Life Sciences Limited | 7.09 Million INR | -354537.875% |
| Eris Lifesciences Limited | 27.81 Billion INR | 9.507% |
| Valiant Laboratories Limited | 767.08 Million INR | -3181.081% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -566.437% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | -148.825% |
| Ipca Laboratories Limited | 14.38 Billion INR | -74.982% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -2420.896% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 23.118% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -656.214% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | -1114.865% |
| Laurus Labs Limited | 25.77 Billion INR | 2.349% |
| Piramal Pharma Limited | 47.1 Billion INR | 46.565% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -3372.18% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 37.423% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -390.464% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | -104.469% |
| Unichem Laboratories Limited | 2.47 Billion INR | -916.857% |
| Sequent Scientific Limited | 4.87 Billion INR | -416.076% |
| Novartis India Limited | 69.7 Million INR | -36009.971% |
| Wanbury Limited | 1.16 Billion INR | -2060.685% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -3772.314% |
| Wockhardt Limited | 23.56 Billion INR | -6.828% |
| Themis Medicare Limited | 957.92 Million INR | -2527.422% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -28049.704% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 31.308% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -14577.309% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | -25.718% |
| Divi's Laboratories Limited | 30 Million INR | -83795.5% |
| NATCO Pharma Limited | 3.71 Billion INR | -578.035% |
| Gufic Biosciences Limited | 3.32 Billion INR | -656.007% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -7582.738% |
| Ind-Swift Limited | 10.13 Billion INR | -148.213% |
| Procter & Gamble Health Limited | 95.6 Million INR | -26227.04% |
| FDC Limited | 205.18 Million INR | -12166.321% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -1201.179% |
| Granules India Limited | 13.15 Billion INR | -91.387% |
| Medicamen Biotech Limited | 308.17 Million INR | -8067.079% |
| Alkem Laboratories Limited | 14.18 Billion INR | -77.443% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -54635.875% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -573348.394% |
| Brooks Laboratories Limited | 56.41 Million INR | -44510.238% |
| Megasoft Limited | 1.47 Billion INR | -1611.606% |
| ZIM Laboratories Limited | 1.08 Billion INR | -2212.776% |
| Neuland Laboratories Limited | 953.89 Million INR | -2538.511% |
| Morepen Laboratories Limited | 289.99 Million INR | -8579.084% |
| Hikal Limited | 8.17 Billion INR | -207.843% |
| Indoco Remedies Limited | 6.71 Billion INR | -274.556% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -782.337% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -7853.06% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -2455.387% |
| Hester Biosciences Limited | 2.44 Billion INR | -929.907% |